300289.SZ
利德曼
SZSE · Healthcare · C 制造业 · CN
CNY 5.75
−3.20%Aug 6, 2026, 12:23 UTC
Leadman's subsidiary Beijing Xiansheng Xiangrui Biological Products Co., Ltd. obtained clinical trial approval from the National Medical Products Administration for its recombinant serogroup B meningococcal vaccine, agreeing to conduct clinical trials to prevent epidemic cerebrospinal meningitis caused by Neisseria meningitidis serogroup B.
Source:Jul 30, 2026, 10:43 UTC
Leadman Biochemistry discloses cumulative litigation involving approximately 106 million yuan.
Source:Jul 17, 2026, 08:38 UTC
Lidman Biotech completed the acquisition of a 61.50% stake in Xiansheng Xiangrui for 1.393 billion yuan, with the shares transferred and the first tranche of payment made.
Source: